Soligenix, Inc. (SNGX) 股票分析

公司概述

Soligenix, Inc. (SNGX) operates as a late-stage biopharmaceutical company dedicated to the development and commercialization of therapeutic products designed to address rare diseases within the United States market. The organization functions through two distinct segments, specifically Specialized BioTherapeutics and Public Health Solutions, which collectively define its operational scope and strategic focus. This entity is categorized within the broader Healthcare sector and the more specific Biotechnology industry, positioning it as a developer of specialized medical interventions rather than a diversified consumer goods provider. The company currently maintains a market capitalization of $11.85M and employs 13 individuals to execute its mission. These financial metrics indicate a small-cap enterprise with limited market dominance, suggesting that the firm is still in an early or growth-oriented phase where capital efficiency and specialized expertise are more critical than broad revenue generation.

财务健康

The company reports a Net Income (TTM) of $-11,080,380 and an EBITDA of $-11,842,252, while specific Revenue (TTM) figures are not disclosed in the available data. The substantial gap between reported revenue and negative net income, compounded by significant EBITDA losses, reveals a cost structure characterized by high operating expenses typical of pre-revenue or late-stage biotech firms, where research and development costs heavily outweigh current sales. Free Cash Flow stands at $-6,309,460, indicating that the company is consuming cash reserves to fund its operations and development pipeline rather than generating liquidity from current activities. All three margin metrics—Gross Margin, Operating Margin, and Profit Margin—are recorded at 0.0%, which signifies that the company has not yet achieved profitability or that its cost of goods sold and operating expenses fully consume its revenue, a common characteristic of early commercialization stages. The balance sheet shows Cash assets of $7.94M against Debt liabilities of $358,144, resulting in a Debt to Equity ratio of 6.77, which implies a highly leveraged capital structure relative to equity, although the low absolute debt amount suggests leverage is driven by a small equity base rather than excessive borrowing. The Current Ratio is 2.39, indicating that the company possesses 2.39 dollars of current assets for every dollar of current liabilities, which suggests adequate short-term liquidity to meet obligations despite the negative cash flow. Return on Equity is -235.5% and Return on Assets is -81.3%, metrics that reveal management is currently unable to generate positive returns on the capital invested, reflecting the inherent risk and capital intensity of the biotechnology sector.

估值评估

Valuation multiples for Soligenix, Inc. present a complex picture due to the lack of profitability; the P/E Ratio (TTM) is N/A because the company has no positive earnings, while the Forward P/E is listed as -1.35, implying that expected earnings are negative or that valuation models using forward earnings are not standard for this loss-making entity. The Price to Book ratio stands at 1.49, indicating that the market values the company at 1.49 times its book value, which may reflect the value of intangible assets like intellectual property or potential future cash flows that are not captured on the balance sheet. The Price to Sales ratio is N/A, and the EV/EBITDA is -0.36, suggesting that traditional multiple-based valuation methods are inapplicable or yield negative valuations due to the lack of earnings and sales data. The stock has experienced significant volatility over the last year, trading between a 52-Week Low of $1.00 and a 52-Week High of $6.23. Based on the available price range, the current market price sits within a wide band of uncertainty, having surged from the low end to over six times that level, highlighting the speculative nature of the investment. The Beta value is 1.94, which means the stock's price volatility is significantly higher than the broader market, moving nearly twice as much as the market index during periods of fluctuation.

Growth & Income

Regarding growth metrics, Revenue Growth (YoY) and Earnings Growth (YoY) are both listed as N/A, meaning historical growth rates cannot be calculated or verified from the current data set. Without positive earnings, the company does not distribute dividends, resulting in a Dividend Yield of N/A and a Payout Ratio of 0.0%. Consequently, the company retains all available cash flow, including the $7.94M in cash, to reinvest into its R&D pipeline and operational expansion rather than paying out income to shareholders. The overall growth and income profile is characterized by a complete reliance on external capital markets and internal cash reserves to fund operations, with no current contribution to shareholder income through dividends. This profile is typical for late-stage biopharmaceutical companies that prioritize product development and regulatory approval over immediate profitability or income distribution.